 |
- Last updated refers to the date when our listing for each treatment was last updated.
- ID is our internal ID - starting with VT.
- Min Karnofsky is a general guide to how well you have to function to use this treatment
- For trials that also have a NCT number, you can click that number to pop up the listing from the clinicaltrials.gov website.
|
|
|
|
|
|
Treatment Name: |
|
Phase I / II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Carboplatin in Adults with Recurrent Glioblastoma Multiforme
|
|
|
|
|
|
|
Keywords: |
|
Vorinostat, Isotretinoin, Carboplatin |
|
|
|
|
Phase: |
|
Phase 1/2 |
|
|
|
|
|
|
Treatment ID#s: |
|
VT1851
2006-0709
|
|
|
|
|
Age Group: |
|
Adults Only |
|
|
|
|
|
|
Min Karnofsky Score: |
|
Not Specified |
|
|
|
|
Conditions: |
|
Newly Diagnosed: N
Recurrent: Y
Prior Surgery is Allowed
Prior Radiation is Allowed
Prior Chemotherapy is Allowed
Patients with histologically proven supratentorial glioblastoma multiforme, gliosarcoma or anaplastic glioma will be eligible for the Phase I component of this protocol. Anaplastic gliomas include anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma, or malignant glioma NOS. Patients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of a malignant glioma is made. Only patients with histologically proven supratentorial glioblastoma multiforme or gliosarcoma will be eligible for the Phase II component.
|
|
|
|
|
|
|
Last Updated: |
|
04/15/2008 |
|
|
|
|
Tumor Types: |
|
Anaplastic Astrocytoma
Glioblastoma Multiforme
Gliosarcoma
Mixed Glioma
Oligodendroglioma High Grade |
|
|
|
|
|
|
|
Comments: |
|
cRA has shown activity in gliomas, but patients may fail treatment due to development of retinoid resistance. Overcoming such resistance by use of vorinostat, a histone deacetylase inhibitor, could enhance the activity of retinoids. Additionally, this activity could also be enhanced by cytotoxic agents such as carboplatin. We hypothesize that the combination of cytotoxic and cytostatic agents will result in prolonged TTP and improved survival.
Analysis of tumor tissue before and after treatment may help to delineate the subset of patients for which the therapy is more effective. We propose to determine the effect of vorinostat on histone acetylation in tumor tissue in a subset of surgical patients.
It will be important to determine if any survival benefit is associated with improvement in symptoms, or if the increase in survival is offset by a clinical worsening. The MDASI-BT allows the self-reporting of symptom severity and interference with daily activities, to find the best treatment with the least toxicity. |
|
|
|
|
|
|
Treatment Type: |
|
Chemotherapy
Less-Toxics. |
|
|
|
|
Contact: |
|
MD Anderson Cancer Center
Jan Esenwein
Program Coordinator, Brain Tumor Program
Contact: Jan Esenwein or Marie Woodward
1515 Holcombe Blvd
Houston, TX 77030-
Phone:(713)745-2264
Fax: (713)794-4999
Click here to send an email
Website: www.mdanderson.org/diseases/braincancer/ |
|
|
|
|
